News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,837 Results
Type
Article (42341)
Company Profile (436)
Press Release (672060)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (208768)
Career Advice (2021)
Deals (36011)
Drug Delivery (104)
Drug Development (83584)
Employer Resources (173)
FDA (16434)
Job Trends (15099)
News (352840)
Policy (33089)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (87)
Alliances (50971)
ALS (94)
Alzheimer's disease (1431)
Antibody-drug conjugate (ADC) (139)
Approvals (16424)
Artificial intelligence (270)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (287)
Cancer (2323)
Cardiovascular disease (186)
Career advice (1689)
Career pathing (30)
CAR-T (158)
Cell therapy (446)
Cervical cancer (19)
Clinical research (67789)
Collaboration (877)
Company closure (1)
Compensation (541)
Complete response letters (24)
COVID-19 (2648)
CRISPR (45)
C-suite (253)
Cystic fibrosis (105)
Data (2242)
Decentralized trials (2)
Denatured (28)
Depression (51)
Diabetes (275)
Diagnostics (6429)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (108)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87882)
Editorial (41)
Employer branding (21)
Employer resources (147)
Events (115990)
Executive appointments (743)
FDA (17717)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (785)
Gene editing (113)
Generative AI (20)
Gene therapy (329)
GLP-1 (749)
Government (4505)
Grass and pollen (4)
Guidances (67)
Healthcare (19146)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (130)
Indications (30)
Infectious disease (2793)
Inflammatory bowel disease (144)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (311)
IPO (16790)
IRA (43)
Job creations (3701)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (498)
Leadership (18)
Legal (7986)
Liver cancer (76)
Lung cancer (328)
Lymphoma (156)
Machine learning (7)
Management (58)
Manufacturing (314)
MASH (70)
Medical device (13530)
Medtech (13535)
Mergers & acquisitions (19762)
Metabolic disorders (721)
Multiple sclerosis (82)
NASH (19)
Neurodegenerative disease (102)
Neuropsychiatric disorders (33)
Neuroscience (2005)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (39)
Obesity (387)
Opinion (223)
Ovarian cancer (77)
Pain (91)
Pancreatic cancer (84)
Parkinson's disease (155)
Partnered (21)
Patents (236)
Patient recruitment (113)
Peanut (47)
People (58696)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21303)
Phase II (29911)
Phase III (22116)
Pipeline (1228)
Policy (148)
Postmarket research (2601)
Preclinical (9139)
Press Release (67)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (404)
Real estate (6015)
Recruiting (66)
Regulatory (22754)
Reports (46)
Research institute (2416)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (77)
Series A (140)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3762)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (40)
The Weekly (48)
Vaccines (709)
Venture capitalists (43)
Weight loss (255)
Women's health (37)
Worklife (17)
Date
Today (157)
Last 7 days (950)
Last 30 days (2691)
Last 365 days (33705)
2025 (11039)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47417)
2018 (35697)
2017 (33033)
2016 (32350)
2015 (38406)
2014 (32189)
2013 (27124)
2012 (29226)
2011 (29868)
2010 (27999)
Location
Africa (736)
Alabama (58)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (39266)
Australia (6533)
California (6274)
Canada (2030)
China (536)
Colorado (273)
Connecticut (288)
Delaware (151)
Europe (85822)
Florida (916)
Georgia (207)
Idaho (57)
Illinois (555)
India (25)
Indiana (312)
Iowa (12)
Japan (164)
Kansas (107)
Kentucky (25)
Louisiana (11)
Maine (62)
Maryland (915)
Massachusetts (4759)
Michigan (222)
Minnesota (398)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1764)
New Mexico (30)
New York (1770)
North Carolina (1036)
North Dakota (8)
Northern California (2715)
Ohio (207)
Oklahoma (14)
Oregon (38)
Pennsylvania (1395)
Puerto Rico (12)
Rhode Island (34)
South America (1110)
South Carolina (23)
South Dakota (1)
Southern California (2344)
Tennessee (101)
Texas (926)
United States (23746)
Utah (183)
Virginia (151)
Washington D.C. (64)
Washington State (575)
West Virginia (3)
Wisconsin (55)
714,837 Results for "allay therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan
Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
December 18, 2023
·
4 min read
Press Releases
Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery
February 18, 2025
·
3 min read
Press Releases
Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery
December 4, 2024
·
3 min read
Business
Allay Therapeutics Appoints Nicole Vitullo to Board of Directors
Allay Therapeutics announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.
September 6, 2023
·
2 min read
Drug Development
Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-Surgical Pain Following Total Knee Replacement Surgery
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced plans to proceed to a Phase 2b registration trial of its lead investigational product ATX101.
June 12, 2024
·
4 min read
Press Releases
Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management
October 24, 2024
·
12 min read
Drug Development
Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the results from a Phase 2B clinical study of its lead investigational product ATX101.
April 11, 2024
·
7 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
Press Releases
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
April 30, 2025
·
8 min read
1 of 71,484
Next
